Dan
The failure rate of stage 2 and 3 clinical trials due to poor efficacy is high - P3 is over 54%.
IMM phase 2b efficacy data is disappointing for sure. Thus far......wait for OS
Must admit I was lower than a snakes belly after announcement. It's a tough business.
Market cap smashed and retail holders (generalisation) run for the hills.
A New approved drug takes up to 10 years and average cost over $2 billion to get to market.
IMM is not PRR and the strategy is to develop multiple products and license out to big pharma
Objective- multiple income streams that fund development of novel immuno - oncology and autoimmune drugs
AND provide shareholders with a great return on investment- dividends.
Definitely a set-back with AIPAC trial but the real anomaly is the placebo arm not Efti that performed as expected.
Thomas Edison didn't give up after his first light bulb didn't work - that said Immutep do not have as many chances to prove Efti works.
TACTI-002 looking great.
Updated data soon if positive would help sentiment- if not positive, game over imo
- Forums
- ASX - By Stock
- IMM
- CYTLIMIC positive results - YNP01 Phase 1 trial
CYTLIMIC positive results - YNP01 Phase 1 trial, page-11
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $486.6M |
Open | High | Low | Value | Volume |
32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 311433 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 113721 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 311433 | 0.330 |
3 | 89973 | 0.325 |
10 | 137686 | 0.320 |
5 | 75745 | 0.315 |
5 | 99268 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 113721 | 6 |
0.340 | 1320656 | 5 |
0.345 | 94973 | 3 |
0.350 | 509080 | 5 |
0.355 | 40082 | 2 |
Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online